GALENA BIOPHARMA INC COM
RXII
RXII was delisted on the 25th of October, 2011.
90 hedge funds and large institutions have $14.4M invested in GALENA BIOPHARMA INC COM in 2016 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 6 closing their positions.
376% more call options, than puts
Call options by funds: $3.93M | Put options by funds: $825K
333% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 6
75% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 16
27% more funds holding
Funds holding: 71 → 90 (+19)
62% less capital invested
Capital invested by funds: $38.2M → $14.4M (-$23.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$450K |
| 2 |
State Street
Boston,
Massachusetts
|
+$164K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$114K |
| 4 |
Goldman Sachs
New York
|
+$90.1K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
-$148K |
| 2 |
D.E. Shaw & Co
New York
|
-$97.5K |
| 3 |
Citigroup
New York
|
-$64.2K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$53.6K |
| 5 |
Morgan Stanley
New York
|
-$39.3K |
RXII Hedge Fund Activity: Q2 2016 in Review
90 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in GALENA BIOPHARMA INC COM (RXII) for Q2 2016, worth a combined $14.4M — down 62% from $38.2M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RXII positions and 6 closed out — a net gain of 20 holders — while 28 added to existing stakes and 16 trimmed.
The largest buyer was Group One Trading, opening a new position worth an estimated $450K. The largest seller was Parallax Volatility Advisers, exiting entirely with an estimated $148K sold.
- 90 institutional investors held GALENA BIOPHARMA INC COM (RXII) as of Q2 2016, up from 71 in Q1 2016.
- Funds reported $14.4M of GALENA BIOPHARMA INC COM stock for Q2 2016, down 62% quarter-over-quarter.
- 26 funds opened new GALENA BIOPHARMA INC COM positions in Q2 2016 and 6 closed out, a net change of +20 holders.
- The largest GALENA BIOPHARMA INC COM buyer in Q2 2016 was Group One Trading, an estimated $450K added.
- The largest GALENA BIOPHARMA INC COM seller in Q2 2016 was Parallax Volatility Advisers, an estimated $148K sold.
Based on aggregated 13F filings for Q2 2016.